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Abstract 
Multiple sclerosis is a neurological disease that affects mil-
lions of people worldwide, yet is not entirely understood. 
Symptoms of multiple sclerosis most frequently include mus-
cle spasms and extreme fatigue, but patients can experience 
a wide variety of issues. There are four categories in which 
patients with multiple sclerosis are typically classified: re-
lapse-remitting, primary-progressive, secondary-progressive 
and progressive-relapsing. The pathophysiology of the dis-
ease is largely unknown, but many theories are being re-
searched. Currently, there are treatments that can alleviate 
symptoms and halt disease progression, but no cure is 
known at this time. Most symptomatic relief medications 
focus on anti-inflammatory mechanisms of action, while dis-
ease modifying treatments have novel mechanisms which 
are being studied more fully. By being aware of new drug 
therapies, pharmacists can better counsel patients with this 
disease state. As new therapies are approved, it is important 
to understand their mechanism and reasons for use, so as to 
be aware of potential side effects and interactions. 
Introduction to Multiple Sclerosis 
Multiple sclerosis (MS) is a chronic inflammatory neurologi-
cal disease that affects 2.1 million people worldwide includ-
ing about 400,000 AmericansP An estimated 200 Americans 
are diagnosed with MS every week.2 The hallmark of MS is a 
progressive autoimmune-mediated demyelination of neu-
rons. The myelin sheath acts as an insulator, providing high 
resistance and low capacitance, resulting in greater impulse 
conduction velocity of neurons.3 Thus, demyelination leads 
to slowed or blocked signal transmission. MS is characteristi-
cally idiopathic, in that a defined pathophysiology has not 
been determined. However, studies suggest a strong genetic 
influence, as first-degree relatives of an affected individual 
are 20 times more likely to be diagnosed with MS than the 
general population. In addition, case studies have found that 
patients with MS have elevated levels of antibodies targeting 
Epstein-Barr virus proteins, suggesting the virus may initiate 
inflammatory responses that lead to autoimmune demyelina-
tion, characteristic of MS.4-6 The onset of symptoms and diag-
nosis typically occurs between the ages of 20 and 50; women 
are two to three times more likely to be affected by MS than 
men. 
Symptoms 
The symptoms of MS are common to many neurologic disor-
ders and are erratic, affecting the muscles, bowel, bladder, 
eyes, brain and spine.6 The most frequent symptoms associ-
ated with MS are fatigue and muscle spasticity. However, 
affected individuals may also experience muscle stiffness, 
disequilibrium, paralysis of the limbs and bowel, mood and 
behavioral changes such as depression, impaired vision, 
slurred speech and incontinence. Symptoms range in inten-
sity from mild to severe, with high inter-patient variability. 
The degree of discomfort and disability associated with MS 
depends on the frequency and severity of attacks, and the 
area of the nervous system affected. MS is typically identified 
by differential diagnosis due to high variability in patient 
presentation and symptom commonality with other neu-
rologic disorders.2 
Effective management of symptoms improves quality of life 
and is imperative to prevent permanent damage that can 
result in disease progression and worsening symptoms.1 
Pharmacological treatments may include corticosteroids to 
decrease inflammation in nervous tissue and reduce the du-
ration and severity of flare-ups. Muscle relaxants, such as 
tizanidine (Zanaflex®) or baclofen (Lioresel®), reduce stiff-
ness and muscle spasticity. Plasma exchange may also be 
used for patients who do not benefit from corticosteroid 
therapy and experience sudden, severe attacks of MS-related 
disability. The antiviral drug amantadine (Symmetrel®) or 
the stimulant modafinil (Provigil®) may be used for fatigue-
like symptoms. An anticholinergic medication such as 
tolterodine (Detrol®) may be used for incontinence by block-
ing contractions of the bladder.6 Since mood and behavioral 
symptoms are also common, antidepressants can be used in 
MS patients, while non-pharmacological approaches such as 
physical, speech or occupational therapy may help maintain 
independence in activities of daily living. Individual or group 
therapy can help with the emotional stress of coping with the 
disease. Assistive devices such as a wheelchair, walker or 
shower chair, as well as a healthy lifestyle and planned exer-
cise program, have also been noted to help with some of the 
movement issues a patient will experience. As with many 
diseases, avoiding illness, stress and fatigue with plenty of 
relaxation and rest can improve symptoms. 
Clinical Classification of Multiple Sclerosis 
Multiple sclerosis can be loosely classified into one of four 
clinical categories: relapse-remitting, primary-progressive, 
secondary-progressive and progressive-relapsing.7 The fol-
lowing descriptions are used for the four categories: 
Relapse-Remitting MS (RRMS): Patients experience bouts of 
worsening neurologic function known as relapses. These 
flare-ups last anywhere from a few days to months and are 
contrasted by periods of remission characterized by full or 
partial recovery, during which no disease progression oc-
curs. The flare-ups must last at least 24 hours and be sepa-
rated from the previous attack by at least one month. No two 
flare-ups are alike. They may include just one symptom or 
involve multiple symptoms. Most patients are initially diag-
nosed in this category but many will progress to secondary-
progressive MS. 
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Primary-Progressive MS (PPMS): The hallmark of PPMS is a 
worsening neurologic function from disease onset, without a 
clear pattern of relapse and remission. 
Secondary-Progressive MS (SPMS): This classification is an 
example of the blurred boundaries between classifications 
because it is difficult to clearly distinguish it from PPMS due 
to their similarities. It is characterized as worsening of neu-
rological function, with more irreversible damage occurring, 
with or without flare-ups and minor relapses. Thus, over 
time, symptoms associated with relapse become worse, 
while remissions are less prominent and shorter in duration, 
eventually becoming non-existent. 
Progressive-Relapsing MS (PRMS): This classification is rela-
tively rare. Patients experience a steady worsening of the 
disease from the beginning without remissions. Patients may 
experience clearly-defined relapses that may slow after some 
time; however, the disease is always continuing to progress. 
Pharmacotherapy 
Currently no cure for MS exists; however, treatment options 
are available for patients based on an anti-inflammatory 
strategy to slow disease progression.1.2 First-line treatments 
are intramuscular or subcutaneous interferon 13 (Rebif®) and 
subcutaneous glatiramer acetate (Copaxone®), both of which 
are indicated for RRMS. The exact mechanism of action of 
interferon 13 is unknown. However, it has been proposed to 
suppress the T-helper cell response, thereby diminishing T-
cell migration across the blood-brain barrier, which reduces 
the inflammatory process. Common adverse effects consist of 
flu-like symptoms, depression and elevated hepatic enzymes. 
The mechanism of action of glatiramer acetate is not fully 
understood, but is thought to involve alteration of T-cell acti-
vation and differentiation. Common adverse effects are simi-
lar to those seen with interferon 13, including injection-site 
reactions and depression, as well as lipoatrophy. These two 
drugs should be avoided in patients with a coexisting depres-
sive disorder. The BEYOND, BECOME and REGARD trials 
compared the two first-line agents and found them to have 
comparable efficacy, with no significant differences regard-
ing relapse rate, disability progression or magnetic reso-
nance imaging (MRI) outcomes.i.a.9 
Second-line agents are intravenous mitoxantrone 
(Novantrone®) and intravenous natalizumab (Tysabri®).2 
Mitoxantrone was the first approved disease-modifying ther-
apy indicated for multiple MS classifications (RRMS, SPMS, 
PRMS).1.2 Mitoxantrone works by intercalating DNA and in-
hibiting topoisomerase II. This results in DNA breaks and 
inhibition of DNA repair, causing reduced proliferation of B-
and T-cells and reduced release of inflammatory cytokines. 
This agent is associated with rare but serious side effects of 
cardiotoxicity and severe bone marrow suppression, thus it 
is not considered a first-line agent. More common adverse 
effects associated with treatment include nausea, vomiting, 
alopecia and leukopenia. Mitoxantrone is used when patients 
progress from RRMS to a more severe stage of MS. The other 
second-line agent, natalizumab, is a humanized monoclonal 
antibody that inhibits leukocytes from crossing the blood-
brain barrier by antagonizing a4 integrins on leukocytes.1 
This monoclonal is not a first-line agent due to its association 
with progressive multifocal leukoencephalopathy (PML), a 
potentially fatal infection caused by the JC polyomavirus. The 
more common adverse events are headache, fatigue, allergic 
reaction and infection. These two treatments are reserved 
for patients who cannot tolerate or are unresponsive to first-
line agents. 
Emerging Therapies: FDA Approved 
Two new agents were approved by the Food and Drug Ad-
ministration (FDA) in 2010 for the treatment of MS, both 
with novel mechanisms relative to existing therapies-
dalfampridine (Ampyra®) and fingolimod (Gilenya®).3 Dal-
fampridine is the only FDA approved symptom management 
treatment to improve walking in all types of MS. Although 
there is disagreement on the exact mechanism by which dal-
fampridine exerts its therapeutic effects, it is classified as a 
voltage-dependent potassium channel blocker that lowers 
the seizure threshold. Studies showed efficacy in one-third of 
patients and the most common adverse effects were falls, 
urinary tract infections, insomnia, asthenia, headache, nau-
sea and dizziness. 
The second medication, fingolimod, is considered a disease-
modifying treatment, and is a sphingosine 1-phosphate 
receptor modulator. In vivo, fingolimod is a prodrug which 
has a phosphorylated active metabolite that exerts its thera-
peutic effects by decreasing the release of autoreactive lym-
phocytes. This lowers the amount of peripheral lymphocytes 
and sequesters lymphocytes in the lymph nodes.10 There is 
also potential for neuroprotective and/or reparative func-
tions.11 Importantly, with this novel mechanism, it is the first 
FDA approved oral treatment for relapsing forms of MS and 
is now considered first-line treatment for RRMs.uo Fingoli-
mod is metabolized by CYP4F2; however, drug-drug interac-
tions are not likely because other drugs currently on the 
market are not metabolized by this enzyme.10 The most com-
mon adverse effects experienced were headache, influenza, 
diarrhea, back pain, liver enzyme elevations and cough. 
Serious adverse events of bradycardia, MS relapse, basal cell 
carcinoma and chest pain occurred in less than 1 percent of 
patients. Recent reports of patient deaths after taking the 
first dose of fingolimod have also led to label changes guiding 
practitioners in appropriate patient populations. The 
updated FDA label for Gilenya® indicates that all patients 
initiating treatment with Gilenya® should have an electrocar-
diogram (ECG) prior to the first dose of the medicine and 
after the six-hour first-dose observation period in addition to 
hourly measurement of blood pressure and heart rate.12 
Additionally, specific initiation guidance for patients is now 
provided to better aid health care providers. Further, there 
are revised recommendations on how to re-initiate therapy 
should Gilenya® be interrupted. 
Emerging Therapies: New Labeling in Clinical Trials 
In addition, several medications are under investigation for 
new labeling in the treatment of MS that are currently ap-
proved for different indications. These are cladribine 
(Leustatin®) and the monoclonal antibodies alemtuzamab 
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(Campath®), daclizumab (Zenapax®) and rituximab 
(Rituxan®). Cladribine was approved in 1993 for the treat-
ment of hairy cell leukemia.13 Currently a variety of studies 
exist evaluating the use of cladribine in treatment of MS as an 
add-on to interferon f3 or an oral formulation.14 Cladribine is 
hypothesized to exert its effects as an immunomodulatory 
purine analog with lymphocytotoxic activity. This would act 
by damaging DNA and thereby cause selective cell death of 
lymphocytes.2 It is generally well-tolerated, with adverse 
effects of headache, nasopharyngitis, upper respiratory tract 
infection, urinary tract infection, alopecia and sensory 
disturbances. Monoclonal antibodies exert their effects by 
recognizing specific target antigens ultimately resulting in 
differing immunosuppressive mechanisms. Alemtuzumab 
and daclizumab are both humanized monoclonal antibodies 
that are slightly less immunogenic due to only one small non-
human portion in the complement sequence. Alemtuzumab 
reduces the number of circulating T-cells, while daclizumab 
antagonizes IL-2 on activated lymphocytes, which is respon-
sible for the up-regulation of the immune system. Rituximab 
is a chimeric monoclonal antibody causing more immuno-
genic reactions due to the presence of the murine antigen-
binding domain. It exerts its effects by selectively depleting 
CD20 pre-B-cells and B-cells ultimately causing cytotoxicity. 
The major concern with monoclonal antibodies would be the 
adverse effect profile requiring careful monitoring of their 
use with other immunosuppressant medications. This con-
comitant use may cause depletion of multiple cell lines, 
which could lead to potentially serious infections. Adverse 
effects associated with these monoclonal antibodies are 
systemic immune responses such as mouth ulcers, photosen-
sitivity rash, transient formation of autoantibodies, lym-
phopenia, lymphadenopathy and transient increases in 
bilirubin concentration. 
Emerging Therapies: Orphans in Clinical Trials 
Three immunomodulator medications are currently in clini-
cal trials for new MS treatments: laquinimod, teriflunomide 
and dimethyl fumarate.2 The mechanism of action of laquini-
mod has not been fully defined, but is proposed to work via 
immunomodulatory properties with potential neuroprotec-
tion.1s Infiltration of leukocytes into the central nervous 
system (CNS) leads to destruction of white matter and neuro-
logical impairment. It is hypothesized that laquinimod acts 
by reducing demyelination and axonal degeneration via 
changes in the cytokine shift. Studies have shown laquinimod 
to be generally well-tolerated, with minimal differences be-
tween the placebo and laquinimod groups regarding adverse 
effects.2 Teriflunomide exerts its effects via anti-inflammatory 
and antiproliferative properties.is Teriflunomide is the active 
metabolite of leflunomide, a commonly used treatment in 
rheumatoid arthritis. Thus far, it has exhibited a favorable 
safety profile and efficacy in the treatment of aspects of rheu-
matoid arthritis that are similar to the autoimmune reaction 
in MS patients. Teriflunomide exerts its effects by decreasing 
activation of T-cells by antigen presenting cells.2 Dimethyl 
fumarate is an orally administered immunomodulatory agent 
that inhibits microglia and astrocytes via the Nrf2 signaling 
pathway, resulting in reduced CNS inflammation. I The most 
common side effects were abdominal pain and flushing 
(Table 1). 
Pharmacist's Role 
With approximately 400,000 Americans diagnosed with MS, 
pharmacists play a critical role in improving patient out-
comes. Continued development of an increasing number of 
novel treatment modalities make it imperative for pharma-
cists to be informed on the current therapies. In addition, 
with the recent approval of oral medications to treat MS, the 
Table 1. Potential Indications for Emerging MS Therapiesz 
Drug RRMS SPMS PPMS 
Fingolimod + + NR 
Laquinimod + + NR 
Teriflunomide + + NR 
Dimethyl Fumarate + NR NR 
Cladribine NR + + 
Alemtuzumab + NR NR 
Daclizumab + + NR 
Rituximab + NR + 
NR= not reported 
Adapted from Gawronski, et al. Table 3 p 921. 
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role of the pharmacist is no longer limited to inpatient clini-
cal monitoring and counseling but has expanded to include 
the outpatient setting. Thus, it is increasingly likely pharma-
cists will be needed for the education of patients as well as 
other health care professionals on current and emerging 
treatments for MS. 
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